Search results for " drug-drug interactions"

showing 2 items of 2 documents

The impact of polypharmacy and drug interactions among the elderly population in Western Sicily, Italy.

2017

Aim: Primary endpoint was to report polypharmacy distribution in the general population vs ≥65 years old people and to examine the frequency of drug–drug interactions (DDIs) in the Health Local Unit of Palermo, Italy, in relationship with patients’ age. Methods: Drug prescription data for the year 2014 were extracted from the database of the Local Health Unit of Palermo Province, Italy. Patients were divided into five age groups (0–13, 14–64, 65–69, 70–74, and ≥75 year old). The detection of potential DDIs in polypharmacy profiles was performed with NavFarma software (Infologic srl, Padova, Italia), with DDI classification provided by tool Micromedex Drug Reax (Truven Health Analitics, Mich…

DrugMaleAgingPediatricsmedicine.medical_specialtyDatabases Factualmedia_common.quotation_subjectDrug interactionPopulationDrug prescription030204 cardiovascular system & hematologySettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineDrug Utilization ReviewAge groupsElderly populationInternal medicinemedicineClinical endpointHumansDrug Interactions030212 general & internal medicineSettore SECS-S/05 - Statistica SocialeMedical prescriptioneducationSicilymedia_commonAgedPolypharmacyeducation.field_of_studyElderly populationbusiness.industrySignificant differenceAge FactorsMiddle AgedContraindicated drug-drug interactions.Population SurveillanceChronic DiseaseSettore BIO/14 - FarmacologiaPolypharmacyFemaleGeriatrics and GerontologybusinessAging clinical and experimental research
researchProduct

Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients

2021

Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic diseases associated with increased morbidity and reduced quality of life. Age may represent a risk factor for adverse events, due to the multimorbidity and polypharmacy, common in elderly patients. Elderly are often not included in clinical trials evaluating efficacy and safety of study drugs for the treatment of inflammatory bowel diseases. Several drugs, such as aminosalicylates, systemic corticosteroids, immunosuppressant drugs, biological drugs and Janus Kinase inhibitors, are available for the management of inflammatory bowel diseases. With the increasing spectrum of therapeutic options, it is th…

safetyPolypharmacydrug-drug interactionsmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismInflammatory bowel disease elderly patients safety drug-drug interactionsGastroenterologyDiseaseelderly patientsmedicine.diseaseInflammatory bowel diseaseUlcerative colitisInflammatory bowel diseaseVedolizumabClinical trialUstekinumabInternal MedicinemedicineAdverse effectIntensive care medicinebusinessmedicine.drugMinerva Gastroenterology
researchProduct